Cynata Therapeutics has achieved a manufacturing milestone for stem cells and is now able to scale up manufacturing of its mesenchymal stem cells (MSCs) for therapeutic use. The company’s platform technology, Cymerus, has been successfully validated at  Waisman Biomanufacturing in Madison, WI, confirming this stem cell manufacturing process is capable of producing MSCs for therapeutic application, consistently and efficiently, in a GMP production environment.   The Cymerus process uses an ...